Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Polarean Imaging plc (PLLWF)
London, NC, US
Polarean Imaging plc operates as a specialized entity within the medical imaging sector, focusing on integrated drug-device solutions. The company extends its services across international markets, including the United States, Canada, Germany, and the United Kingdom. At its core, Polarean is engaged in the creation and market introduction of advanced gas polarizer systems and associated ancillary instruments. A significant aspect of their innovation lies in developing specialized equipment that enhances conventional magnetic resonance imaging (MRI) machines, enabling them to perform advanced functional pulmonary imaging. The company distinguishes itself by specializing in the application of hyperpolarized xenon gas (129Xe) as a unique imaging agent. This technology allows for the detailed visualization of regional ventilation and gas exchange within the lungs, particularly in the smallest airways, the interface between the lung tissue and the bloodstream, and the pulmonary vasculature, thereby offering a novel diagnostic method. Furthermore, Polarean Imaging plc is actively involved in the design and manufacturing of the specific MRI radiofrequency coils that are indispensable for imaging 129Xe within an MRI system. Established in 2016, the company's base of operations is located in Durham, North Carolina.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +560.00% | +0.00% | -40.00% | -97.68% | -99.50% | -97.22% | -97.22% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+246.8% ★ Q2'25: +342.3% (vs Q2'23)
-
EPS growth Medical - Devices: +28.5%+87.2% ★ Q2'25: +87.3% (vs Q2'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%-204.2% Q2'25: -821.1% (vs Q2'23)
-
EBIT margin Medical - Devices: +6.2%-275.9% Q2'25: -849.8% (vs Q2'23)
-
ROIC Medical - Devices: +3.3%-1,594.2% Q2'25: -2,027.5% (vs Q2'23)
-
Share dilution Medical - Devices: 0.0%+463.3% Q2'25: +466.5% (vs Q2'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.07× Q2'25: -0.02× (vs Q2'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.44M
est: 1.85M (+31.8%)
|
2.30M
est: 2.06M (+11.9%)
|
1.06M
est: 1.00M (+5.7%)
|
1.19M
est: 2.50M (-52.6%)
|
1.03M
est: 1.00M (+3.3%)
|
890.9K
est: 800.0K (+11.4%)
|
3.09M
est: 2.96M (+4.5%)
|
3.00M
est.
|
5.80M
5.80M – 5.80M
+93.3% YoY
|
16.60M
16.60M – 16.60M
+186.2% YoY
|
32.60M
32.60M – 32.60M
+96.4% YoY
|
| EBITDA |
-4.64M
est: -1.85M (-150.8%)
|
-5.24M
est: -2.06M (-154.7%)
|
-5.85M
est: -1.00M (-484.8%)
|
-13.52M
est: -2.50M (-440.9%)
|
-12.78M
est: -1.00M (-1,178.1%)
|
-11.19M
est: -800.0K (-1,299.4%)
|
-7.56M
est: -2.96M (-155.6%)
|
-3.00M
est.
|
-5.80M
-5.80M – -5.80M
-93.3% YoY
|
-16.60M
-16.60M – -16.60M
-186.2% YoY
|
-32.60M
-32.60M – -32.60M
-96.4% YoY
|
| EBIT |
-5.27M
est: -1.85M (-184.7%)
|
-6.01M
est: -2.06M (-192.4%)
|
-6.62M
est: -1.00M (-561.6%)
|
-14.32M
est: -2.50M (-472.7%)
|
-13.67M
est: -1.00M (-1,267.1%)
|
-12.15M
est: -800.0K (-1,419.3%)
|
-8.52M
est: -2.96M (-188.3%)
|
-3.00M
est.
|
-5.80M
-5.80M – -5.80M
-93.3% YoY
|
-16.60M
-16.60M – -16.60M
-186.2% YoY
|
-32.60M
-32.60M – -32.60M
-96.4% YoY
|
| Net Income |
-5.45M
est: -87.38M (+93.8%)
|
-6.10M
est: -42.35M (+85.6%)
|
-6.53M
est: -41.18M (+84.1%)
|
-14.02M
est: -92.66M (+84.9%)
|
-13.91M
est: -72.07M (+80.7%)
|
-11.88M
est: -61.78M (+80.8%)
|
-8.54M
est: -14.73M (+42.0%)
|
-9.66M
est.
|
-9.66M
-9.66M – -9.66M
+0.0% YoY
|
-6.04M
-6.04M – -6.04M
+37.5% YoY
|
3.62M
3.62M – 3.62M
+160.0% YoY
|
| SGA |
6.19M
est: 14.24M (-56.5%)
|
6.33M
est: 15.83M (-60.0%)
|
5.97M
est: 7.70M (-22.5%)
|
13.89M
est: 19.25M (-27.8%)
|
12.14M
est: 7.70M (+57.7%)
|
6.90M
est: 6.16M (+12.0%)
|
5.05M
est: 22.76M (-77.8%)
|
23.10M
est.
|
44.65M
44.65M – 44.65M
+93.3% YoY
|
127.80M
127.80M – 127.80M
+186.2% YoY
|
250.98M
250.98M – 250.98M
+96.4% YoY
|
| EPS |
-0.08
est: -0.07 (-7.7%)
|
-0.06
est: -0.04 (-62.2%)
|
-0.04
est: -0.03 (-27.5%)
|
-0.07
est: -0.08 (+7.3%)
|
-0.07
est: -0.06 (-9.9%)
|
-0.06
est: -0.05 (-8.4%)
|
-0.01
est: -0.01 (+41.8%)
|
-0.01
est.
|
-0.01
-0.01 – -0.01
+0.0% YoY
|
-0.01
-0.01 – -0.01
+37.5% YoY
|
0.00
0.00 – 0.00
+160.0% YoY
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Christopher Richard Von Jako | Chief Executive Officer & Director | 551.5K | — |
| Charles Fremont Osborne Jr. | Chief Financial Officer & Director | 346.8K | male |
| Kenneth Paul West | Non-Executive Chairman of the Board | 70.0K | male |
| Chase Hall | Chief Medical Advisor | — | — |
| Alex Dusek | Chief Commercial Officer | — | male |
| Neil Wadehra | Vice President of Operations | — | male |
| Stephen Austin | Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PLLWF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
